Long-term use of sildenafil

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 3, 2003, Pages 397-405

  Carson, Culley C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Erectile dysfunction; Phosphodiesterase inhibitors; Sildenafil

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIALLERGIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; APOMORPHINE; ARGININE; AZITHROMYCIN; CIMETIDINE; CYCLIC GMP; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; ERYTHROMYCIN; KETOCONAZOLE; MACROLIDE; PHENTOLAMINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROSTAGLANDIN E1; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SILDENAFIL; TADALAFIL; TRAZODONE; UNINDEXED DRUG; VARDENAFIL; YOHIMBINE; ZAPRINAST;

AREA UNDER THE CURVE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR EFFECT; CLINICAL STUDY; CLINICAL TRIAL; CORPUS CAVERNOSUM; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG USE; DYSPEPSIA; ENZYME ACTIVITY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART ARRHYTHMIA; HUMAN; LONG TERM CARE; MUSCLE RELAXATION; NONHUMAN; NOSE CONGESTION; PENIS ERECTION; PHARMACODYNAMICS; RETINA ROD; REVIEW; SMOOTH MUSCLE; STRUCTURE ACTIVITY RELATION; VISUAL DISORDER;

AGED; AREA UNDER CURVE; CENTRAL NERVOUS SYSTEM DISEASES; CHRONIC DISEASE; HEPATITIS, TOXIC; HUMANS; IMPOTENCE; KIDNEY DISEASES; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 0037350305     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.3.397     Document Type: Review

References (46)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA (1995) 270:83-90.
2. FELDMAN AH, GOLDSTEIN I, HATZICHRISTOU DG et al.: Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J. Urol. (1994) 151:54-61.
3. CARSON CC, WEST SL, GLASSER DB et al.: Prevalence and correlates of erectile dysfunction. A United States nationwide population base sample: Phase I results. J. Urol. (2002) 167:29.
4. DERBY CA, MOHR BA, GOLDSTEIN I et al.: Modifiable risk factors and erectile dysfunction: can a lifestyle change modify risk? Urology (2000) 56:302-306.
5. BENET AE, MELMAN A: The epidemiology of erectile dysfunction. Urol. Clin. North Am. (1975) 2:699-709.
6. Contemporary Urology 2002 - 2003 Fact Book. Thompson Medical Economics, NJ, USA (2002):46.
7. TELOKEN C, RHODEN E, SOGARI P et al.: Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J. Urol. (1998) 159:122-124.
8. MORALES A, CONDRA M, OWEN J et al.: Is yohimbine effective in the treatment of organic impotence? J. Urol. (1987) 137:1168-1172.
9. SAENZDETEJADA I, WARE JC, BIANCO R et al.: Pathophysiology of prolonged penile erection associated with trazodone use. J. Urol. (1991) 145:60-64.
10. CARSON CC, MINO RD: Priapism associated with trazodone therapy. J. Urol. (1988) 139:369-370.
11. ZORGNIOTTI A, LIZZA E: Effective large doses of the NO precursor L-arginine on erectile function. Int. J. Impot. Res. (1994) 6:33-35.
12. CHEN J, WOLLMAN Y, CHERNICHOVSKY T, IAINA A, SOFER M, MATZKIN H: Effective oral administration of high dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double blind randomized placebo controlled study. BJU. Int. (1999) 83:269-271.
13. GOLDSTEIN I, CARSON CC, ROSEN R, ISLAM A: Vasomax for the treatment of male erectile dysfunction. World J. Urol. (2001) 19:51-56.
14. HEATON JLM: Key issues from the clinical trials of apomorphine SL. World J. Urol. (2001) 19:25-31.
15. CORBIN JD, FRANCIS SH, WEBB DJ: Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology (2002) 60(Suppl. 2B):4-11.
16. KRANE R, BROCK G, EARDLEY I et al.: Oral non endocrine treatment. In: Erectile Dysfunction: First International Consultation on Erectile Dysfunction. Jardin A, Wagner G, Khoury S et al. (Eds) Health Publication Limited, Plymouth, UK (2000):258-261.
17. MORELAND RB, GOLDSTEIN I, TRAISH A: Sildenafil: a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci. (1998) 62:PL309-PL318.
18. GOLDSTEIN I, LUE T, PADMA-NATHAN H et al.: Oral sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med. (1998) 338:1397-1404.
19. PADMA-NATHAN H, STEERS WD, WICKER PA: Efficacy and safety of oral sildenafil and the treatment of erectile dysfunction: a double blind placebo controlled study of 329 patients. Int. J. Clin. Prac. (1998) 53:1-4.
20. NICHOLS DJ, MUIRHEAD GJ, HARNESS JA. Pharmacogenetics of sildenafil after single oral doses in healthy male subjects: absolue bioavailability, food effects, and dose proportionality. Br. J. Clin. Pharmacol. (2002) 53:5S-12S.
21. WALKER DK, ACKLAND MJ, JAMES GC et al.: Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog, and man. Xenobiotica (1999) 29:297-310.
22. MUIRHEAD GJ, ALLEN MJ, JAMES GC et al.: Pharmacokinetics of sildenafil, a selective cGMP PDE 5 inhibitor, after single oral doses in fasted and fed healthy volunteers. Br. J. Clin. Pharmacol. (1996) 42:268P.
23. MUIRHEAD GJ, RONCE DJ, WALKER DK, WASTOLL P: Comparative human pharmacokinetics and metabolism of a single dose oral and intravenous sildenafil citrate. J. Clin. Pharm. (2002) 53(Suppl.):135-215.
24. JACKSON G: Phosphodiesterase 5 inhibition effects on the coronary vasculature. Int. J. Clin. Pract. (2001) 55:183-188.
25. CHIANG CE, LUK HN, WANG TM, DING PY: Effects of sildenafil on cardiac repolarization. Cardiovasc. Res. (2002) 55:290-299.
26. GHOFRANI HA, WIEDEMANN R, ROSE F et al.: Sildenafil for treatment of lung fibrosis in pulmonary hypertension: a randomized controlled trial. Lancet (2002) 360:895-900.
27. WALLIS RM, CORBIN JD, FRANCIS SH, ELLIS P: Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissues cyclic nucleotides, platelet function in the contractile responses of trabeculate carneae in aortic rings in vitro. Am. J. Cardiol. (1999) 83(5A):3C-12C.
28. HERMANN HC, CHANG G, KLUGHERZ BD et al.: Hemodynamic effects of sildenafil in men with severe coronary artery disease. N. Engl. J. Med. (2000) 342:1622-1626.
29. JACKSON G, BENJAMIN N, JACKSON N et al.: Effects of sildenafil citrate on human hemodynamics. Am. J. Cardiol. (1999) 83(Suppl. 5A):13C-20C.
30. LATIES A, ELLIS P, MOLLON JD: The effects of sildenafil citrate on color discrimination in volunteers and patients with erectile dysfunction. Invest. Ophthalmol. Vis. Sci. (1999) 40:S693.
31. MUIRHEAD GJ, WILNER K, COLBURN W et al.: The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate. Br. J. Pharmacol. (2002) 53:215-305.
32. PRICKAERTS J, VAN STAVERN WC, SIK A et al.: Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience (2002) 113(2):351-361.
33. OCKAILI R, SALLOUM F, HAWKINS J et al.: Sildenafil induces powerful cardio protective effect via opening of mitochondrial K(ATP) channels in rabbits. Am. J. Physiol. Heart Circ. Physiol. (2002) 283:H1263-H1269.
34. CARSON CC, BURNETT AL, LEVINE LA, NEHRA A: The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology (2002) 60(Suppl. 2B):12-27.
35. BOOLELL M, ALLEN MJ, BALLARD SA et al.: Sildenafil: an orally active type 5 cyclic GMP specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. (1996) 8:47-52.
36. PADMA-NATHAN h, EARDLEY I, KLONER RA et al.: A four year update on the safety of sildenafil. Urology (2002) 60(Suppl. 2B):67-90.
37. MORALES A, GINGELL C, COLLINS M et al.: Clinical safety of oral sildenafil citrate in the treatment of erectile dysfunction. Int. J. Impot. Res. (1998) 10:69-74.
38. CARSON CC, SIEGEL RL, ORAZEM J: Sildenafil citrate treatment for erectile dysfunction: rate of adverse events decreases with time. J. Urol. (2002) 167(Suppl.):179.
39. CHEITLIN MD, HUTTER AM Jr, BRINDIS RG et al.: ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J. Am. Coll. Cardiol. (1999) 33:273-283.
40. MCCULLOUGH AR, BARADA JH, FAWZY A et al.: Achieving treatment optimization with sildenafil citrate in patients with erectile dysfunction. Urology (2002) 60(Suppl. 2B):28-38.
41. ROSEN RC, RILEY A, WAGNER G et al.: The International Index for Erectile Function (IIEF): a multidimensional scale for assessment of erectile function. Urology (1997) 49:822-830.
42. JAROW JP, BURNETT AL, GERINGER AM: Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J. Urol. (1999) 162:722-725.
43. DERRY F, HULTLING C, SEFATEL AD et al.: Efficacy and safety of sildenafil citrate in men with erectile dysfunction and spinal cord injury: a review. Urology (2002) 60(Suppl. 2B):49-57.
44. YOUNG JM, BENNETT C, GILHOOLY P et al.: Efficacy and safety of sildenafil in Black and Hispanic American men. Urology (2002) 60(Suppl. 2B):39-48.
45. NURNBERG HG, SEIDMAN SN, GELENBERG AJ et al.: Depression, anti-depressant therapy in erectile dysfunction: clinical trials of sildenafil citrate in treated and untreated patients with depression. Urology (2002) 60(Suppl. 2B):58-66.
46. EI GALLEY R, RUTLAND H, TALIC R et al.: Long term efficacy of sildenafil and tachyphylaxis effect. J. Urol. (2001) 166:927-931.